Galectin Therapeutics Anticipates Relocation of Corporate Headquarters to Gwinnett
Leader in galectin science and drug development chooses metro Atlanta
(GWINNETT- METRO ATLANTA) September 10, 2012 – Gwinnett Chamber Economic Development joins with Galectin Therapeutics in celebrating the relocation of its corporate headquarters to Gwinnett County, metro Atlanta. Galectin Therapeutics, a leader in galectin science and drug development to treat fibrotic disease and cancer, will move its corporate offices next month from the Boston area to its new facility, located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross.
Galectin Therapeutics chose Gwinnett County based on its advantageous proximity to the University of Georgia’s Complex Carbohydrate Research Center, one of the world’s premier centers for carbohydrate research, and the robust research and clinical assets throughout metro Atlanta. The Norcross facility will now house Galectin Therapeutics’ executive, strategic and development functions, while its Boston location will continue selected lab-based product development.
“This reorganization is an important move for the Company that will strengthen our ability to deliver on the promise of our carbohydrate-based therapeutic agents and afford us greater opportunities to attract highly-skilled talent in the field of carbohydrates to our Company,” said Peter G. Traber, MD, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “We will be able to expand on the work we are doing with the world-class researchers at the Complex Carbohydrate Research Center, while maintaining the excellent work being done with our collaborators at SBH Sciences. In addition to enhancing our development activities, the move and re-organization will decrease our operations expenses which we will put back into our programs in liver fibrosis and cancer.”
“We welcome Galectin Therapeutics to Georgia’s thriving bioscience community, where it will find numerous opportunities to collaborate with our outstanding research institutions,” said Chris Cummiskey, Commissioner of the Georgia Department of Economic Development. “The state has worked hard to cultivate an environment that will help bioscience companies grow, and Galectin Therapeutics’ decision to locate here is a significant testimonial to the strength of our assets.”
“Gwinnett County and metro Atlanta offer an array of resources and incentives that foster a pro-business atmosphere, educated workforce and excellent quality of life,” stated Gwinnett County Commission Chairman Charlotte Nash. “We are fortunate that Galectin Therapeutics has chosen to relocate its business to Gwinnett and look forward to seeing them expand and enhance our bioscience community.”
The relocation of Galectin Therapeutics to Gwinnett County positions the company within the region’s Innovation Crescent, which is both a geographic area and coalition of more than a dozen counties and life science and economic development entities, all dedicated to supporting Georgia’s life science growth. The Innovation Crescent, anchored by Atlanta on one end and Athens-Clarke County on the other, encompasses the resources of top research organizations in the Southeast to further life science research. A member of this coalition, Gwinnett Chamber Economic Development works to promote and support the expansions and relocations of health science and service companies and it is considered a target sector industry for the Gwinnett community.
“Galectin Therapeutics’ relocation to Gwinnett County speaks volumes to the area’s biotechnology environment and advantageous location to research facilities,” stated Kellie Brownlow, Director of Economic Development for Gwinnett Chamber Economic Development and Partnership Gwinnett. “This is yet another example of a growing company choosing to move to Gwinnett—a community which attracts, encourages, and supports its biotechnology industry.”